- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Lindsey Roeker: Adding Rituximab to Venetoclax in Patients With CLL
Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center, discusses adding rituximab to venetoclax to allow for a 2-year fixed-duration treatment schedule for patients with chronic lymphocytic leukemia (CLL).
Adding rituximab to venetoclax allows for a 2-year fixed duration treatment schedule for patients with chronic lymphocytic leukemia, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
Transcript:
What are some factors that predict outcomes for patients with CLL who use venetoclax alone or venetoclax with rituximab?
So we know that there are genetic features that make people higher risk when treated with venetoclax, and those are well-defined genetic features. We've used real-world evidence to look at whether how much that anti-CD20 antibody is adding to venetoclax. And really, I think the role that plays is allowing for a time-limited therapy per the MURANO data. So adding rituximab to venetoclax allows for a 2-year fixed duration treatment schedule, whereas venetoclax as a monotherapy has traditionally been used as an ongoing therapy. I think the role of the CD20 is really, we have data to say that that can be a time-limited therapy.
Can biosimilar rituximab help make combination therapy for patients with CLL more cost effective?
Absolutely. I think as we have more options that are more affordable, these will be options that are available for more patients all around the world. And I think that's a really exciting opportunity. I think within academic communities, I think that there will be uptake. It's unclear to me what the practitioners in the community are going to be doing. I have less of a finger on the pulse there.
Newsletter
Stay up to date on the most recent and practice-changing, delivering expert insights, regulatory updates, and clinical trial news on biosimilars.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
